Ondansetron Hydrochloride is a 5-HT3 receptor antagonist indicated for prevention of nausea and vomiting from chemotherapy, radiotherapy and surgery. We supply it to US manufacturers of tablets, orally disintegrating tablets, oral solution and injection.
Data from PubChem (CID 59774) and FDA’s substance registry
CAS number
103639-04-9
Molecular formula
C18H24ClN3O3
Molecular weight
365.9g/mol
FDA UNII
IUPAC name
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one;dihydrate;hydrochloride
InChIKey
VRSLTNZJOUZKLX-UHFFFAOYSA-N
- Appearance
- White to off-white powder.
- Solubility
- Soluble in water and in normal saline.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Supplied as the dihydrate. Say whether you need oral or injection grade. Ondansetron base, used in orally disintegrating tablets, is a separate API.
On the US market
- Reference product
- ZofranNDA 020007
- Approved ANDAs
- 29 with a marketed product
- Approved forms and strengths
- Injection 2 mg/mL
- Tablet 4 mg, 8 mg, 24 mg
- Oral solution 4 mg/5 mL
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. Strengths of salt forms are stated as the active moiety. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com